Study Finds Redlined Neighborhoods Face Delays in Emergency Care
By I. Edwards HealthDay Reporter

FRIDAY, Aug. 15, 2025 — People living in neighborhoods once labeled “hazardous” on federal housing maps are still more likely to wait longer for an ambulance, new research shows.
Rutgers University researchers who analyzed 236 U.S. urban areas found that 7.06% of residents in historically redlined “Grade D” areas lacked quick access to emergency medical services (EMS).
That compared to 4.36% in “Grade A” neighborhoods favored by lenders nearly a century ago.
The gap existed in every U.S. region, the study found. It was especially wide in the Great Lakes region, where residents of redlined neighborhoods were nearly three times as likely to live outside a five-minute ambulance reach.
“Location alone determines whether people get the rapid care that saves lives,” said Dr. Cherisse Berry, a professor of surgery at Rutgers New Jersey Medical School in Newark who is also a trauma surgeon.
Overall, researchers found that 2.2 million people — or 5.34% of the 41 million living in mapped areas — cannot count on an ambulance arriving within the five minutes benchmarked by the National Fire Protection Association for critical calls.
The odds of response times exceeding five minutes were 67% higher in redlined neighborhoods, researchers explained.
The study — published Aug. 5 in JAMA Network Open — used historic Home Owners’ Loan Corporation (HOLC) maps, 2020 U.S. Census data and modern traffic information to measure driving times from more than 42,000 EMS stations.
HOLC grades — green for “best,” blue for “still desirable,” yellow for “declining” and red for “hazardous” — were used in the 1930s to guide mortgage lending. While outlawed in 1968, these guides have had lasting effects, researchers noted.
Today, historically redlined neighborhoods often have higher Black and Hispanic populations, lower median incomes and higher population density than areas with better HOLC grades, the researchers explained.
Every 10 minute delay in hospital arrival can raise trauma death rates by 8%, Berry said. As such, focusing on improving emergency response in these neighborhoods could have immediate benefits.
“It is time to dismantle the structural determinants of health that perpetuate preventable deaths," Berry said in a news release.
"Historical redlining and other discriminatory policies have hardwired inequities into our emergency response systems, leaving racially and economically marginalized communities to wait longer for lifesaving care," she said.
Solutions should include embedding "equity metrics" into EMS policy, investing in historically excluded neighborhoods and holding agencies accountable for equitable access, Berry said.
“National and state health policy must treat equitable EMS access as a non-negotiable public health standard, ensuring that the ZIP code where someone is injured never determines whether they live or die,” she said.
Even a minute or two saved could make a life-and-death difference, Berry explained.
It's important to note that the study focused on estimated travel times, not actual EMS records, so factors like dispatch delays or hospital hand-offs weren’t part of the analysis.
Still, a University of Chicago team that wrote an accompanying editorial said the findings offer a “road map” for addressing these inequities.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-08-16 12:00
Read more

- Current Medical Use of Rx Stimulants for ADHD Up in Teens From 2005 to 2023
- Depression Risk Greater In Some Women With Premature Menopause
- HHS Plans to Reform Organ Procurement Protocols
- Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
- Patients With Leukemia Have Higher Infection Risk During Immunoglobulin Replacement Therapy
- Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions